Tuesday, Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804 in patients with moderately to severely active ulcerative colitis or Crohn's disease.
In the DUET-CD study, JNJ-4804a demonstrated higher clinical remission rates and endoscopic response rates than golimumab in patients with Crohn's disease. Moreover, JNJ-4804 showed clinically meaningful improvements at Week 48 across multiple clinical and endoscopic endpoints compared to golimumab and guselkumab monotherapies and placebo.
Meanwhile, in the DUET-UC study, JNJ-4804a demonstrated superior clinical remission rates compared to golimumab in patients with ulcerative colitis, with 41.0% of JNJ-4804-treated patients achieving clinical remission at Week 48 versus golimumab. It also showed clinically meaningful improvements at Week 48 across multiple clinical and endoscopic endpoints compared to golimumab and guselkumab monotherapies and placebo.
Backed by these findings, the company intends to commence the Phase 3 DUET ENCORE-CD trial in adults with moderately to severely active Crohn's disease as well as the Phase 3 DUET ENCORE-UC trial in adults with moderately to severely active ulcerative colitis.
In the pre-market hours, JNJ is trading at $224.21 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.